Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies.

Haanen, John; Los, Christy; Phan, Giao Q; Betof Warner, Allison

Haanen, John; Los, Christy; Phan, Giao Q; Betof Warner, Allison.

Afiliação

Haanen J; Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Los C; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
Phan GQ; Division of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Betof Warner A; Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.

Am Soc Clin Oncol Educ Book ; 44(3): e431608, 2024 Jun.

Article em En | MEDLINE | ID: mdl-38776509

ABSTRACT

ABSTRACT

Lifileucel or TIL has recently been FDA approved for metastatic melanoma patients as first cell therapy for a solid tumor. We discuss roll-out of TIL as new SOC and other upcoming new cell therapies.

Assuntos

Imunoterapia Adotiva; Melanoma; Humanos; Melanoma/terapia; Imunoterapia Adotiva/métodos; Neoplasias/terapia; Resultado do Tratamento

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia Adotiva / Melanoma Limite: Humans Idioma: En Revista: Am Soc Clin Oncol Educ Book Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Holanda País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google